Lenacapavir

YEZTUGO is indicated for pre‑exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 in adults and adolescents weighing at least 35 kg who are at risk for HIV-1 acquisition.

Prescribing label

Selected manufacturer label information, organised into consistent sections by Sofidex. This source is written for healthcare professionals; ask your pharmacist to explain instructions that are unclear. Read the full label at DailyMed ↗

Drug facts

Used for: YEZTUGO is indicated for pre‑exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 in adults and adolescents weighing at least 35 kg who are at risk for HIV-1 acquisition.
Do not take if: YEZTUGO is contraindicated in individuals with unknown or positive HIV-1 status.

What it is used for

YEZTUGO is indicated for pre‑exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 in adults and adolescents weighing at least 35 kg who are at risk for HIV-1 acquisition. Individuals must have a negative HIV-1 test prior to initiating YEZTUGO.

Side effects, and when to stop

The following adverse reactions are discussed in other sections of the labeling:

Serious Injection Site Reactions with Improper Administration.

Who should not take it

YEZTUGO is contraindicated in individuals with unknown or positive HIV-1 status.

Cite this page

NLM: sofidex [Internet]. Daloreum; c2026. Lenacapavir; [reviewed 2026 Aug 3; cited 2026 Nov 10]. Available from: https://sofidex.com/patients/medicines/lenacapavir
APA 7th: sofidex. (2026, August 3). Lenacapavir. Daloreum. Retrieved November 10, 2026, from https://sofidex.com/patients/medicines/lenacapavir
AMA 11th: Lenacapavir. sofidex. Reviewed August 3, 2026. Accessed November 10, 2026. https://sofidex.com/patients/medicines/lenacapavir

The cited date is today’s, because a citation records when you read the page. The reviewed date is when a clinician last checked it.